The disclosure provides a method of treating cancer in a subject in need thereof including administering to the subject a therapeutically-effective amount of an enhancer of a zeste homolog 2 (EZH2) inhibitor. In certain embodiments of this method, the subject has one or more mutations in one or more sequences encoding a gene listed in Tables 1-9, Tables 17-19, and/or Figures 19-22.